

human reproduction **SUPPLEMENTARY DATA**

Supplementary Table S1 AMH levels in tertiles by CED categories.

	n	DCOG LATER-VEVO	n	PanCareLIFE	n	St. Jude Lifetime
CED score 0						
Lowest AMH tertile	22	1.10 (0.01–2.14)	27	0.82 (0.01–1.71)	51	1.09 (0.01–2.20)
Middle AMH tertile	43	2.77 (0.03–4.59)	60	2.20 (0.49–3.38)	54	2.44 (1.14–3.56)
Highest AMH tertile	38	5.81 (2.19–8.60)	74	5.00 (1.93–13.50)	62	4.72 (2.24–10.48)
CED score >0–4000						
Lowest AMH tertile	24	1.17 (0.18–2.14)	16	0.88 (0.05–1.79)	3	0.74 (0.38–1.50)
Middle AMH tertile	25	2.94 (1.13–4.31)	48	2.33 (0.13–3.39)	6	2.01 (1.33–3.05)
Highest AMH tertile	31	5.93 (3.07–12.76)	39	4.71 (1.96–10.94)	4	4.38 (3.58–7.55)
CED score ≥4000–8000						
Lowest AMH tertile	28	0.72 (0.01–1.97)	25	0.68 (0.01–1.68)	26	0.94 (0.15–1.98)
Middle AMH tertile	12	3.14 (1.29–4.42)	26	2.02 (0.13–3.29)	20	2.48 (1.30–3.48)
Highest AMH tertile	12	5.35 (2.36–13.14)	17	4.61 (3.52–18.50)	14	5.03 (3.96–9.21)
CED score ≥8000						
Lowest AMH tertile	17	0.68 (0.01–1.86)	79	0.20 (0.01–1.74)	26	0.76 (0.01–1.95)
Middle AMH tertile	18	1.82 (0.03–4.24)	31	2.00 (0.01–8.89)	22	2.42 (1.32–3.57)
Highest AMH tertile	6	5.11 (2.33–9.44)	23	4.09 (2.04–9.46)	24	3.76 (2.38–11.90)

Values are represented as the median (minimum–maximum), unless indicated otherwise.

AMH, anti-Müllerian hormone in µg/L; CED, cyclophosphamide equivalent dose in mg/m²; PanCareLIFE, PanCareLIFE cohort; St. Jude Lifetime, St. Jude Lifetime Cohort; VEVO, DCOG-LATER VEVO cohort.